Secretory miRNAs as novel cancer biomarkers

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 1, 2012, Pages 32-43

  Zhang, Jian ^a   Zhao, Huadong ^b   Gao, Yuan ^c,d   Zhang, Wei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bio messenger; Biomarkers; Cancer; Secretory miRNAs

Indexed keywords

DOCETAXEL; MICRORNA; MICRORNA 1; MICRORNA 141; MICRORNA 20A; MICRORNA 21; MICRORNA 210; MICRORNA 222; MICRORNA 24; MICRORNA 26A; MICRORNA 29A; MIR 106A; MIR 106B; MIR 1254; MIR 150; MIR 152; MIR 195; MIR 27A; MIR 30D; MIR 486; MIR 499; MIR 638; MIR 92; MIR 92A; MIRAVIRSEN; SECRETORY MICRORNA; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD ANALYSIS; BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG RESPONSE; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LUNG NODULE; LUNG NON SMALL CELL CANCER; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOSARCOMA; RNA ANALYSIS; SECRETION; STOMACH CANCER;

HUMANS; MICRORNAS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859652376     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.03.001     Document Type: Review

References (112)

1. Denli A.M., Tops B.B., Plasterk R.H., Ketting R.F., Hannon G.J. Processing of primary microRNAs by the microprocessor complex. Nature 2004, 432:231-235.
2. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
3. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., Kim V.N. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425:415-419.
4. Seitz H., Zamore P.D. Rethinking the microprocessor. Cell 2006, 125:827-829.
5. M.A. Havens, A.A. Reich, D.M. Duelli, M.L. Hastings, Biogenesis of mammalian microRNAs by a non-canonical processing pathway, Nucleic Acids Res. (in press) [Electronic publication ahead of print].
6. Martello G., Rosato A., Ferrari F., Manfrin A., Cordenonsi M., Dupont S., Enzo E., Guzzardo V., Rondina M., Spruce T., Parenti A.R., Daidone M.G., Bicciato S., Piccolo S. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141:1195-1207.
7. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., Teruya-Feldstein J., Bell G.W., Weinberg R.A. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28:341-347.
8. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Zen K., Zhang C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18:997-1006.
9. Wittmann J., Jack H.M. Serum microRNAs as powerful cancer biomarkers. Biochim. Biophys. Acta 2010, 1806:200-207.
10. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., Curry W.T., Carter B.S., Krichevsky A.M., Breakefield X.O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
11. Zhao H., Shen J., Medico L., Wang D., Ambrosone C.B., Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One 2010, 5:e13735.
12. Zhang H.L., Yang L.F., Zhu Y., Yao X.D., Zhang S.L., Dai B., Zhu Y.P., Shen Y.J., Shi G.H., Ye D.W. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011, 71:326-331.
13. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10513-10518.
14. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8:467-477.
15. Kosaka N., Izumi H., Sekine K., Ochiya T. microRNA as a new immune-regulatory agent in breast milk. Silence 2010, 1:7.
16. El-Hefnawy T., Raja S., Kelly L., Bigbee W.L., Kirkwood J.M., Luketich J.D., Godfrey T.E. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin. Chem. 2004, 50:564-573.
17. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
18. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., Xiao T., Schafer J., Lee M.L., Schmittgen T.D., Nana-Sinkam S.P., Jarjoura D., Marsh C.B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3:e3694.
19. Ohshima K., Inoue K., Fujiwara A., Hatakeyama K., Kanto K., Watanabe Y., Muramatsu K., Fukuda Y., Ogura S., Yamaguchi K., Mochizuki T. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 2010, 5:e13247.
20. Kosaka N., Iguchi H., Yoshioka Y., Hagiwara K., Takeshita F., Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J. Biol. Chem. 2012, 287:1397-1405.
21. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5:845-856.
22. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
23. Gong C., Yao Y., Wang Y., Liu B., Wu W., Chen J., Su F., Yao H., Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 2011, 286:19127-19137.
24. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., Yuen S.T., Chan T.L., Kwong D.L., Au G.K., Liu C.G., Calin G.A., Croce C.M., Harris C.C. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
25. Chung G.E., Yoon J.H., Myung S.J., Lee J.H., Lee S.H., Lee S.M., Kim S.J., Hwang S.Y., Lee H.S., Kim C.Y. High expression of microRNA-15b predicts a low risk of tumor recurrence following curative resection of hepatocellular carcinoma. Oncol. Rep. 2010, 23:113-119.
26. Hu Z., Chen J., Tian T., Zhou X., Gu H., Xu L., Zeng Y., Miao R., Jin G., Ma H., Chen Y., Shen H. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J. Clin. Invest. 2008, 118:2600-2608.
27. Vosa U., Vooder T., Kolde R., Fischer K., Valk K., Tonisson N., Roosipuu R., Vilo J., Metspalu A., Annilo T. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosomes Cancer 2011, 50:812-822.
28. Hildebrandt M.A., Gu J., Lin J., Ye Y., Tan W., Tamboli P., Wood C.G., Wu X. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene 2010, 29:5724-5728.
29. Zhang Y., Yan L.X., Wu Q.N., Du Z.M., Chen J., Liao D.Z., Huang M.Y., Hou J.H., Wu Q.L., Zeng M.S., Huang W.L., Zeng Y.X., Shao J.Y. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011, 71:3552-3562.
30. Schwind S., Maharry K., Radmacher M.D., Mrozek K., Holland K.B., Margeson D., Whitman S.P., Hickey C., Becker H., Metzeler K.H., Paschka P., Baldus C.D., Liu S., Garzon R., Powell B.L., Kolitz J.E., Carroll A.J., Caligiuri M.A., Larson R.A., Marcucci G., Bloomfield C.D. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol. 2010, 28:5257-5264.
31. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., Banham A.H., Pezzella F., Boultwood J., Wainscoat J.S., Hatton C.S., Harris A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141:672-675.
32. Guo H.Q., Huang G.L., Guo C.C., Pu X.X., Lin T.Y. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis. Markers 2010, 29:251-258.
33. Tanaka M., Oikawa K., Takanashi M., Kudo M., Ohyashiki J., Ohyashiki K., Kuroda M. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 2009, 4:e5532.
34. Ohyashiki J.H., Umezu T., Kobayashi C., Hamamura R.S., Tanaka M., Kuroda M., Ohyashiki K. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res. Notes 2010, 3:347.
35. Moussay E., Wang K., Cho J.H., van Moer K., Pierson S., Paggetti J., Nazarov P.V., Palissot V., Hood L.E., Berchem G., Galas D.J. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:6573-6578.
36. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
37. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.
38. Rosell R., Wei J., Taron M. Circulating MicroRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin. Lung Cancer 2009, 10:8-9.
39. Hu Z., Chen X., Zhao Y., Tian T., Jin G., Shu Y., Chen Y., Xu L., Zen K., Zhang C., Shen H. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1721-1726.
40. Xie L., Chen X., Wang L., Qian X., Wang T., Wei J., Yu L., Ding Y., Zhang C., Liu B. Cell-free miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 2010, 10:591.
41. Wei J., Gao W., Zhu C.J., Liu Y.Q., Mei Z., Cheng T., Shu Y.Q. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 2011, 30:407-414.
42. Wang Z.X., Bian H.B., Wang J.R., Cheng Z.X., Wang K.M., De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J. Surg. Oncol. 2011, 104:847-851.
43. Liu X.G., Zhu W.Y., Huang Y.Y., Ma L.N., Zhou S.Q., Wang Y.K., Zeng F., Zhou J.H., Zhang Y.K. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 2012, 29:618-626.
44. Shen J., Liu Z., Todd N.W., Zhang H., Liao J., Yu L., Guarnera M.A., Li R., Cai L., Zhan M., Jiang F. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 2011, 11:374.
45. Shen J., Todd N.W., Zhang H., Yu L., Lingxiao X., Mei Y., Guarnera M., Liao J., Chou A., Lu C.L., Jiang Z., Fang H., Katz R.L., Jiang F. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab. Invest. 2011, 91:579-587.
46. Bianchi F., Nicassio F., Marzi M., Belloni E., Dall'olio V., Bernard L., Pelosi G., Maisonneuve P., Veronesi G., Di Fiore P.P. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 2011, 3:495-503.
47. Boeri M., Verri C., Conte D., Roz L., Modena P., Facchinetti F., Calabro E., Croce C.M., Pastorino U., Sozzi G. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3713-3718.
48. Foss K.M., Sima C., Ugolini D., Neri M., Allen K.E., Weiss G.J. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:482-488.
49. Silva J., Garcia V., Zaballos A., Provencio M., Lombardia L., Almonacid L., Garcia J.M., Dominguez G., Pena C., Diaz R., Herrera M., Varela A., Bonilla F. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur. Respir. J. 2011, 37:617-623.
50. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., Poon T.C., Ng S.S., Sung J.J. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
51. Luo X., Burwinkel B., Tao S., Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer?. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1272-1286.
52. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127:118-126.
53. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., Harris C.C., Chen K., Hamilton S.R., Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6:e17745.
54. Moghimi-Dehkordi B., Safaee A., Zali M.R. Survival rates and prognosis of gastric cancer using an actuarial life-table method. Asian Pac. J. Cancer Prev. 2008, 9:317-321.
55. Zhao Z.S., Wang Y.Y., Ye Z.Y., Tao H.Q. Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol. Oncol. Res. 2009, 15:589-596.
56. Seo J.H., Choi C.W., Kim B.S., Shin S.W., Kim Y.H., Kim J.S., Lee S.W., Choi J.H., Park Y.T., Mok Y.J., Kim C.S. Follow-up study of peripheral blood carcinoembryonic antigen mRNA using reverse transcription-polymerase chain reaction as an early marker of clinical recurrence in patients with curatively resected gastric cancer. Am. J. Clin. Oncol. 2005, 28:24-29.
57. Ishigami S., Natsugoe S., Hokita S., Che X., Tokuda K., Nakajo A., Iwashige H., Tokushige M., Watanabe T., Takao S., Aikou T. Clinical importance of preoperative carcinoembryonic antigen and carbohydrate antigen 19-9 levels in gastric cancer. J. Clin. Gastroenterol. 2001, 32:41-44.
58. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., Konishi H., Morimura R., Deguchi K., Fujiwara H., Okamoto K., Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 2010, 102:1174-1179.
59. Liu R., Zhang C., Hu Z., Li G., Wang C., Yang C., Huang D., Chen X., Zhang H., Zhuang R., Deng T., Liu H., Yin J., Wang S., Zen K., Ba Y., Zhang C.Y. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 2011, 47:784-791.
60. Friedrich M.J. Debate continues on use of PSA testing for early detection of prostate cancer. JAMA 2011, 305:2273-2275.
61. Borofsky M.S., Makarov D.V. Prostate cancer: PSA velocity in prostate cancer screening-the debate continues. Nat. Rev. Urol. 2011, 8:413-414.
62. Moltzahn F., Olshen A.B., Baehner L., Peek A., Fong L., Stoppler H., Simko J., Hilton J.F., Carroll P., Blelloch R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011, 71:550-560.
63. Gonzales J.C., Fink L.M., Goodman O.B., Symanowski J.T., Vogelzang N.J., Ward D.C. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer 2011, 9:39-45.
64. Lodes M.J., Caraballo M., Suciu D., Munro S., Kumar A., Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009, 4:e6229.
65. Brase J.C., Johannes M., Schlomm T., Falth M., Haese A., Steuber T., Beissbarth T., Kuner R., Sultmann H. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128:608-616.
66. Yaman Agaoglu F., Kovancilar M., Dizdar Y., Darendeliler E., Holdenrieder S., Dalay N., Gezer U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011, 32:583-588.
67. Zheng C., Yinghao S., Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med. Oncol. 2011.
68. Houssami N., Abraham L.A., Miglioretti D.L., Sickles E.A., Kerlikowske K., Buist D.S., Geller B.M., Muss H.B., Irwig L. Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer. JAMA 2011, 305:790-799.
69. Untch M., Fasching P.A., Konecny G.E., Hasmuller S., Lebeau A., Kreienberg R., Camara O., Muller V., du Bois A., Kuhn T., Stickeler E., Harbeck N., Hoss C., Kahlert S., Beck T., Fett W., Mehta K.M., von Minckwitz G., Loibl S. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG Study Groups. J. Clin. Oncol. 2011, 29:3351-3357.
70. van de Velde C.J., Rea D., Seynaeve C., Putter H., Hasenburg A., Vannetzel J.M., Paridaens R., Markopoulos C., Hozumi Y., Hille E.T., Kieback D.G., Asmar L., Smeets J., Nortier J.W., Hadji P., Bartlett J.M., Jones S.E. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377:321-331.
71. Zhu W., Qin W., Atasoy U., Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes 2009, 2:89.
72. Heneghan H.M., Miller N., Kelly R., Newell J., Kerin M.J. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010, 15:673-682.
73. Wu Q., Lu Z., Li H., Lu J., Guo L., Ge Q. Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol. 2011, 2011:597145.
74. Wang F., Zheng Z., Guo J., Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 2010, 119:586-593.
75. Li L.M., Hu Z.B., Zhou Z.X., Chen X., Liu F.Y., Zhang J.F., Shen H.B., Zhang C.Y., Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70:9798-9807.
76. Zhang Y., Jia Y., Zheng R., Guo Y., Wang Y., Guo H., Fei M., Sun S. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin. Chem. 2010, 56:1830-1838.
77. Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., Huang L., Li H., Tan W., Wang C., Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011, 50:136-142.
78. Gui J., Tian Y., Wen X., Zhang W., Zhang P., Gao J., Run W., Tian L., Jia X., Gao Y. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. (Lond.) 2011, 120:183-193.
79. Yamamoto Y., Kosaka N., Tanaka M., Koizumi F., Kanai Y., Mizutani T., Murakami Y., Kuroda M., Miyajima A., Kato T., Ochiya T. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009, 14:529-538.
80. Li J., Wang Y., Yu W., Chen J., Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem. Biophys. Res. Commun. 2011, 406:70-73.
81. Qu K.Z., Zhang K., Li H., Afdhal N.H., Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol. 2011, 45:355-360.
82. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., Frazier M.L., Killary A.M., Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila.) 2009, 2:807-813.
83. Ho A.S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.T., Koong A.C. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl. Oncol. 2010, 3:109-113.
84. Yin M., Li C., Li X., Lou G., Miao B., Liu X., Meng F., Zhang H., Chen X., Sun M., Ling Q., Zhou R. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J. Surg. Oncol. 2011, 104:29-36.
85. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
86. Resnick K.E., Alder H., Hagan J.P., Richardson D.L., Croce C.M., Cohn D.E. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 2009, 112:55-59.
87. Yu T., Wu Y., Helman J.I., Wen Y., Wang C., Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol. Cancer Res. 2011, 9:161-172.
88. Park N.J., Zhou H., Elashoff D., Henson B.S., Kastratovic D.A., Abemayor E., Wong D.T. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 2009, 15:5473-5477.
89. Liu C.J., Kao S.Y., Tu H.F., Tsai M.M., Chang K.W., Lin S.C. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Oral Dis. 2010, 16:360-364.
90. Miyachi M., Tsuchiya K., Yoshida H., Yagyu S., Kikuchi K., Misawa A., Iehara T., Hosoi H. Circulating muscle-specific microRNA, miR-206, as a potential diagnostic marker for rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 2010, 400:89-93.
91. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56:1733-1741.
92. Hanson E.K., Lubenow H., Ballantyne J. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs. Anal. Biochem. 2009, 387:303-314.
93. Michael A., Bajracharya S.D., Yuen P.S., Zhou H., Star R.A., Illei G.G., Alevizos I. Exosomes from human saliva as a source of microRNA biomarkers. Oral Dis. 2010, 16:34-38.
94. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., Warnecke J.M., Sczakiel G. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol. Oncol. 2010, 28:655-661.
95. Wang G., Tam L.S., Li E.K., Kwan B.C., Chow K.M., Luk C.C., Li P.K., Szeto C.C. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 2011, 20:493-500.
96. Zubakov D., Boersma A.W., Choi Y., van Kuijk P.F., Wiemer E.A., Kayser M. MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation. Int. J. Legal Med. 2010, 124:217-226.
97. Courts C., Madea B. Specific Micro-RNA signatures for the detection of saliva and blood in forensic body-fluid identification. J. Forensic Sci. 2011, 56:1464-1470.
98. Wong T.S., Liu X.B., Wong B.Y., Ng R.W., Yuen A.P., Wei W.I. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res. 2008, 14:2588-2592.
99. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251:499-505.
100. Zhu H.T., Dong Q.Z., Wang G., Zhou H.J., Ren N., Jia H.L., Ye Q.H., Qin L.X. Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients. Mol. Biotechnol. 2012, 50:49-56.
101. Kato Y. An efficient fluorescent method for selective detection of mature miRNA species. Nucleic Acids Symp. Ser. (Oxf) 2008, 71-72.
102. Roy S., Soh J.H., Gao Z. A microfluidic-assisted microarray for ultrasensitive detection of miRNA under an optical microscope. Lab Chip 2011, 11:1886-1894.
103. Pegtel D.M., Cosmopoulos K., Thorley-Lawson D.A., van Eijndhoven M.A., Hopmans E.S., Lindenberg J.L., de Gruijl T.D., Wurdinger T., Middeldorp J.M. Functional delivery of viral miRNAs via exosomes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:6328-6333.
104. Zhang Y., Liu D., Chen X., Li J., Li L., Bian Z., Sun F., Lu J., Yin Y., Cai X., Sun Q., Wang K., Ba Y., Wang Q., Wang D., Yang J., Liu P., Xu T., Yan Q., Zhang J., Zen K., Zhang C.Y. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell 2010, 39:133-144.
105. Kogure T., Lin W.L., Yan I.K., Braconi C., Patel T. Inter-cellular nanovesicle mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011, 54:1237-1248.
106. Trajkovic K., Hsu C., Chiantia S., Rajendran L., Wenzel D., Wieland F., Schwille P., Brugger B., Simons M. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008, 319:1244-1247.
107. Gibbings D., Voinnet O. Control of RNA silencing and localization by endolysosomes. Trends Cell Biol. 2010, 20:491-501.
108. Kosaka N., Iguchi H., Yoshioka Y., Takeshita F., Matsuki Y., Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J. Biol. Chem. 2010, 285:17442-17452.
109. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., Bennett C.F., Pogosova-Agadjanyan E.L., Stirewalt D.L., Tait J.F., Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5003-5008.
110. Weiss G.J., Bemis L.T., Nakajima E., Sugita M., Birks D.K., Robinson W.A., Varella-Garcia M., Bunn P.A., Haney J., Helfrich B.A., Kato H., Hirsch F.R., Franklin W.A. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann. Oncol. 2008, 19:1053-1059.
111. Nakajima G., Hayashi K., Xi Y., Kudo K., Uchida K., Takasaki K., Yamamoto M., Ju J. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 2006, 3:317-324.
112. Sarasin-Filipowicz M., Krol J., Markiewicz I., Heim M.H., Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat. Med. 2009, 15:31-33.